AU5010793A - Human interleukin-13 - Google Patents

Human interleukin-13

Info

Publication number
AU5010793A
AU5010793A AU50107/93A AU5010793A AU5010793A AU 5010793 A AU5010793 A AU 5010793A AU 50107/93 A AU50107/93 A AU 50107/93A AU 5010793 A AU5010793 A AU 5010793A AU 5010793 A AU5010793 A AU 5010793A
Authority
AU
Australia
Prior art keywords
human interleukin
interleukin
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU50107/93A
Inventor
Gregorio Aversa
Jacques Banchereau
Francine Briere
Robert L. Coffman
Benjamin G Cooks
Janice Culpepper
Warren Dang
Jan De Vries
Rene De Waal Malefyt
Timothy M Doherty
Andrew Heath
Andrew Mckenzie
Juha Punnonen
Gerard Zurawski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/012,543 external-priority patent/US5596072A/en
Application filed by Schering Corp filed Critical Schering Corp
Publication of AU5010793A publication Critical patent/AU5010793A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU50107/93A 1992-08-21 1993-08-18 Human interleukin-13 Abandoned AU5010793A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US93341692A 1992-08-21 1992-08-21
US933416 1992-08-21
US1097793A 1993-01-29 1993-01-29
US010977 1993-01-29
US08/012,543 US5596072A (en) 1992-08-21 1993-02-01 Method of refolding human IL-13
PCT/US1993/007645 WO1994004680A1 (en) 1992-08-21 1993-08-18 Human interleukin-13
US012543 1998-01-23

Publications (1)

Publication Number Publication Date
AU5010793A true AU5010793A (en) 1994-03-15

Family

ID=27359336

Family Applications (1)

Application Number Title Priority Date Filing Date
AU50107/93A Abandoned AU5010793A (en) 1992-08-21 1993-08-18 Human interleukin-13

Country Status (6)

Country Link
EP (1) EP0656947A1 (en)
JP (1) JPH07508179A (en)
AU (1) AU5010793A (en)
CA (1) CA2142860A1 (en)
IL (1) IL106732A0 (en)
WO (1) WO1994004680A1 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2297831T3 (en) 1994-05-09 2008-05-01 Oxford Biomedica (Uk) Limited RETROVIRIC VECTORS THAT PRESENT A REDUCED RECOMBINATION RATE.
US5614191A (en) * 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US6518061B1 (en) 1995-03-15 2003-02-11 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US6428788B1 (en) 1995-03-15 2002-08-06 Penn State University Compositions and methods for specifically targeting tumors
US5830453A (en) * 1995-05-19 1998-11-03 Emory University Use of IL-13 to induce 15-lipoxygenase
US7078494B1 (en) 1996-03-01 2006-07-18 Genetics Institute, Llc Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding
US5710023A (en) 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
US6664227B1 (en) 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
WO1998010638A1 (en) * 1996-09-10 1998-03-19 Amrad Operations Pty. Ltd. Therapeutic molecules
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
US6171856B1 (en) 1997-07-30 2001-01-09 Board Of Regents, The University Of Texas System Methods and compositions relating to no-mediated cytotoxicity
AU8671798A (en) * 1997-07-30 1999-02-22 Betagene, Inc. Methods and compositions relating to no-mediated cytotoxicity
US6482403B1 (en) * 1998-05-29 2002-11-19 Heska Corporation Caniney IL-13 immunoregulatory proteins and uses thereof
USRE40374E1 (en) 1998-05-29 2008-06-10 Heska Corporation Canine IL-13 immunoregulatory proteins and uses thereof
WO1999061618A2 (en) 1998-05-29 1999-12-02 Heska Corporation Canine and feline immunoregulatory proteins, nucleic acid molecules, and uses thereof
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
ES2277460T3 (en) * 1998-12-14 2007-07-01 Genetics Institute, Llc CHAIN OF THE CYTOKIN RECEIVER.
ATE466280T1 (en) * 1998-12-23 2010-05-15 Medsaic Pty Ltd EXPERIMENTAL ARRANGEMENT FOR DETECTING BINDING PARTNERS
GB0004016D0 (en) * 2000-02-22 2000-04-12 Royal Brompton Hospital Biological material and uses thereof
WO2002055100A2 (en) * 2000-10-20 2002-07-18 Genetics Institute, Llc Method and composition for inhibition of tumor growth and enhancing an immune response
JP2005506960A (en) * 2001-06-07 2005-03-10 ワイエス Solution structure of IL-13 and use thereof
US7786282B2 (en) 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
CA2512709A1 (en) * 2003-01-17 2004-08-05 Children's Hospital Medical Center Use of tff2, or agents inducing tff2, in the therapy of allergies
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
KR101073590B1 (en) * 2003-07-15 2011-10-14 메디뮨 리미티드 -13 human antibody molecules for il-13
MX361174B (en) 2003-12-23 2018-11-29 Genentech Inc Novel anti-il 13 antibodies and uses thereof.
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (en) 2004-06-09 2006-07-26 Wyeth Corp ANTIBODIES AGAINST HUMAN INTERLEUQUINE-13 AND USES OF THE SAME
DE602005025525D1 (en) 2004-11-17 2011-02-03 Amgen Inc COMPLETE HUMAN MONOCLONAL ANTIBODIES AGAINST IL-13
AR058104A1 (en) 2005-10-21 2008-01-23 Novartis Ag ORGANIC COMPOUNDS
WO2007137300A2 (en) 2006-05-23 2007-11-29 Bellicum Pharmaceuticals, Inc. Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
KR101676269B1 (en) 2006-09-08 2016-11-15 애브비 바하마스 리미티드 Interleukin-13 binding proteins
KR101923282B1 (en) 2010-12-16 2018-11-28 제넨테크, 인크. Diagnosis and treatments relating to th2 inhibition
US9512194B2 (en) 2012-01-27 2016-12-06 The Board Of Trustees Of The Leland Stanford Junior University Modified IL-13 polypeptides
CA3184564A1 (en) 2013-09-13 2015-03-19 Genentech, Inc. Methods and compositions comprising an anti-il13 antibody and residual hamster phospholipase b-like 2
EP4163633A1 (en) 2013-09-13 2023-04-12 F. Hoffmann-La Roche AG Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products
CA2925417C (en) 2013-09-24 2023-10-24 Fahar Merchant Interleukin-4 receptor-binding fusion proteins and uses thereof
GB2600564B (en) 2019-04-19 2024-02-28 Synerkine Pharma B V A fusion protein comprising IL13

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU217099B (en) * 1991-03-29 1999-11-29 Elf Sanofi Sa. Process for producing a protein having cytokine-type activity, recombinant dna coding for this protein, transformed cells, and micro-organisms

Also Published As

Publication number Publication date
EP0656947A1 (en) 1995-06-14
JPH07508179A (en) 1995-09-14
IL106732A0 (en) 1993-12-08
CA2142860A1 (en) 1994-03-03
WO1994004680A1 (en) 1994-03-03

Similar Documents

Publication Publication Date Title
AU5010793A (en) Human interleukin-13
ZA936097B (en) Human interleukin-13
AU3802493A (en) Surgical endoclip
AU4166393A (en) Auto-reclosers
AU3888793A (en) Novel medicament
AU3561193A (en) TNF-muteins
AU3991693A (en) Pyrazinoindoles
AU3042892A (en) Rockbolt
AU4177593A (en) Benzophenonehydrazones
AU5953794A (en) Tampon
AU685767B2 (en) Substituted benzazepinones
AU4014193A (en) Chair
AU4156393A (en) Heterocyclyltriazolinones
AU3263493A (en) Tonometer
AU4348493A (en) Inhaler
AU5737494A (en) Human thrombospondin-4
AU664253B2 (en) Photo-deviometer
AU5666994A (en) T-configured wheelchair
AU3461693A (en) Saddle-cloth
AU3562193A (en) Morpholin- and thiomorpholin-4-ylamides
AU2446192A (en) Mild soap-synbar
AU5063493A (en) Fitting
AU4164793A (en) Heterocyclyltriazolinones
AU4632493A (en) Weathershed
AU5112193A (en) Chair